(TSX:IMP),(OTC US:ITMSF),(Other OTC:ITMSF), Company reports first quarter 2025 revenue growth of 153% with 28% pro-forma adjusted EBITDA margin Confirms projected 2025 revenue of $30-35 million and 28% EBITDA margin Conference call today at 5:00 pm ET to discuss results DENVER, May 15, 2025 (GLOBE NEWSWIRE) — Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the […]

(NASDAQ:TRIB), DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) — Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2024 and the fiscal year then ended. Key Highlights and Developments Management continues to make significant progress

(NASDAQ:OTLK),(NASDAQ:OTLKW), LYTENAVA(TM) (bevacizumab gamma) on track for planned first commercial launches in Germany and the United Kingdom (UK) in Q2 CY2025 Prescription Drug User Fee Act (PDUFA) goal date of August 27, 2025 in the United States ISELIN, N.J., May 15, 2025 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on

(NASDAQ:SCWO), Multiple Deployments Scheduled throughout 2025 to Showcase AirSCWO Technology Launched Waste Destruction Services and Signed RCRA Part B TSDF Partner Agreement to Expand Onsite Operations New Executive Team and Director Appointments to Drive Commercial Trajectory DURHAM, N.C., May 15, 2025 (GLOBE NEWSWIRE) — 374Water Inc. (NASDAQ: SCWO) (“374Water”) (the “Company”), a global leader in

(NASDAQ:IPSC), Patient dosing initiated in Phase 1 CALiPSO-1 trial evaluating CNTY-101 in autoimmune disease; expanding to additional U.S. and European sites following CTA authorizations in Germany, France, and Italy CNTY-308 expected to enter IND-enabling studies in mid-2025 to support anticipated clinical trials in B-cell-mediated autoimmune diseases and malignancies Presentations at ASGCT 28th Annual Meeting highlight

(NasdaqGM:SEPN), Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later in 2025 Expect to Initiate Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast

(NasdaqGM:KPLT),(NasdaqGM:KPLTW), Expects Growth to Accelerate In Second QuarterReiterates 2025 Guidance PLANO, Texas, May 15, 2025 (GLOBE NEWSWIRE) — In the press release issued by Katapult Holdings, Inc. on May 15, 2025, in the gross originations by quarter table, Q4 in FY 2024 should be $75.2 million instead of $64.2 million. The updated release reads: Katapult

(NASDAQ:AENT), Delivered $1.9M in net income, a $5.3M year-over-year improvement, showcasing strong execution and margin gains Reduced revolver debt by 25% year-over-year, strengthening balance sheet and liquidity position Direct to Consumer sales reach 35% of gross revenue PLANTATION, Fla., May 15, 2025 (GLOBE NEWSWIRE) — Alliance Entertainment Holding Corporation (Nasdaq: AENT), a premier distributor and

(NasdaqGM:RENT), NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) — Rent the Runway, Inc. (“Rent the Runway”) (Nasdaq: RENT) announced today that it expects to release its first quarter 2025 financial results for the quarter ended April 30, 2025 on Thursday, June 5, 2025, after market close. Rent the Runway will host a conference call and

(NASDAQ:VTVT), Ongoing screening in CATT1 Phase 3 trial evaluating cadisegliatin in patients with type 1 diabetes (T1D) Topline Phase 3 data for cadisegliatin expected in 2H 2026 HIGH POINT, N.C., May 15, 2025 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin, a potential first-in-class